for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Merck & Co., Inc.

MRK

Latest Trade

84.68USD

Change

0.88(+1.05%)

Volume

7,522,217

Today's Range

83.66

 - 

84.91

52 Week Range

66.10

 - 

87.35

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
83.80
Open
83.71
Volume
7,522,217
3M AVG Volume
176.74
Today's High
84.91
Today's Low
83.66
52 Week High
87.35
52 Week Low
66.10
Shares Out (MIL)
2,560.37
Market Cap (MIL)
216,223.60
Forward P/E
17.14
Dividend (Yield %)
2.61

Next Event

Q3 2019 Merck & Co Inc Earnings Call

Latest Developments

More

4D Pharma Collaborates With MSD To Develop Live Biotherapeutics For Vaccines

Merck’s Keytruda Now Approved As Monotherapy In China

FDA Accepts 2 Applications For Merck's DIFICID (Fidaxomicin) To Treat Children Aged 6 Months To 18 Years With Clostridium Difficile Infections

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Merck & Co., Inc.

Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company's Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed healthcare providers, such as health maintenance organizations, pharmacy benefit managers and other institutions. Vaccine products consist of preventive pediatric, adolescent and adult vaccines, primarily administered at physician offices.

Industry

Biotechnology & Drugs

Contact Info

2000 Galloping Hill Rd

+1.908.7404000

http://www.merck.com/

Executive Leadership

Kenneth C. Frazier

Chairman of the Board, President, Chief Executive Officer

Robert M. Davis

Executive Vice President, Global Services, Chief Financial Officer

Steven C. Mizell

Executive Vice President, Chief Human Resources Officer, Human Resources

Jim Scholefield

Executive Vice President, Chief Information and Digital Officer

Michael T. Nally

Executive Vice President, Chief Marketing Officer

Key Stats

1.82 mean rating - 17 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

39.8K

2017

40.1K

2018

42.3K

2019(E)

46.0K
EPS (USD)

2016

3.780

2017

3.980

2018

4.340

2019(E)

4.925
Price To Earnings (TTM)
22.77
Price To Sales (TTM)
4.87
Price To Book (MRQ)
7.84
Price To Cash Flow (TTM)
15.87
Total Debt To Equity (MRQ)
96.21
LT Debt To Equity (MRQ)
82.40
Return on Investment (TTM)
14.71
Return on Equity (TTM)
11.36

Latest News

Latest News

CORRECTED-BRIEF-WHO Welcomes EMA Recommendation Of Conditional Marketing Authorization For Merck's V920 Ebola Zaire Vaccine

* WORLD HEALTH ORGANIZATION SAYS "WELCOMES" THE EMA ANNOUNCEMENT RECOMMENDING A CONDITIONAL MARKETING AUTHORIZATION FOR MERCK'S V920 EBOLA ZAIRE VACCINE

WHO hails 'triumph' as Merck's Ebola vaccine gets European green light

The world's first Ebola vaccine was recommended for approval by European drugs regulators on Friday in a move hailed by the World Health Organization (WHO) as a "triumph for public health" that would save many lives.

Merck gets EU panel nod for first ever Ebola vaccine

A panel of the European drugs regulator on Friday recommended approving Merck & Co's vaccine for the deadly Ebola virus.

US STOCKS-Apple and Merck drive Wall Street higher as trade worries abate

* Apple up on JPM's iPhone volume forecast raise, Cook's comments

AstraZeneca, Merck ovarian cancer treatment improves progression-free survival

AstraZeneca Plc and Merck & Co Inc said on Monday their treatment for newly diagnosed advanced ovarian

AstraZeneca, Merck cancer treatment attains meaningful improvement in progression-free survival

AstraZeneca Plc and Merck & Co Inc said on Monday their drug to treat a form of ovarian cancer improved progression-free survival in patients tested in a late-stage study.

3rd Circuit revives investors’ claims against Merck over Vytorin/Zetia nondisclosures

Merck & Co must face state-law fraud claims by 16 institutional investors who opted out of class actions alleging the company withheld adverse information about a clinical trial of anti-cholesterol drugs Vytorin and Zetia, a federal appeals court held on Thursday.

Reuters asks judge to release secret Propecia documents

Reuters asked a U.S. judge on Thursday to unseal documents filed in court regarding potential risks associated with Propecia, Merck & Co's popular baldness drug.

FDA flags serious risks with hepatitis C drugs from AbbVie, Gilead and Merck

The U.S. Food and Drug Administration said on Wednesday it had identified 63 cases of worsening liver function in certain patients taking hepatitis C medicines made by drugmakers Merck & Co Inc, Gilead Sciences and AbbVie Inc.

HHS to provide $23 million to Merck for Ebola vaccine production

The U.S. Department of Health and Human Services (HHS) said on Wednesday it will fund the manufacturing of Merck & Co Inc's investigational Ebola vaccine called V920, in response to the outbreak of the deadly virus in the Democratic Republic of the Congo (DRC).

Breakingviews - The Exchange: Nile Rodgers and Merck Mercuriadis

How much is a song worth? Two people who should know are the Chic founder and his manager, who have started a company to buy some of the world’s most famous back catalogues. They explain how music investing works and why many songwriters are miffed with Spotify.

IN BRIEF: Merck says U.S. probing ties to electronic health record vendors

Drugmaker Merck & Co Inc has disclosed that it has received a series of subpoenas as part of a U.S. investigation related to a cloud-based electronic health records company that Allscripts Healthcare Solutions Inc acquired last year.

UPDATE 1-GSK ends development of Ebola vaccine, hands work to U.S. institute

British drugmaker GlaxoSmithKline is giving up its work on developing three potential vaccines against the deadly Ebola and Marburg viruses, despite an ongoing Ebola outbreak in Democratic Republic of Congo.

Cancer drug Keytruda, vaccines propel Merck to quarterly profit beat

Merck & Co Inc <MRK.N> reported better-than-expected second-quarter results on Tuesday and raised its full-year earnings forecast on strong demand for its blockbuster cancer immunotherapy Keytruda and vaccines.

Merck profit surges on strong sales of Keytruda, vaccines

U.S. drugmaker Merck & Co Inc reported a 56.4% rise in second-quarter profit on Tuesday, boosted by strong demand for its Keytruda immunotherapy, the dominant treatment for lung cancer, as well as higher sales of its vaccines.

Merck's treatment for urinary, abdominal infections gets FDA approval

The U.S. Food and Drug Administration has approved Merck & Co Inc's combination treatment for complicated forms of urinary tract and abdominal infections, the drugmaker said on Wednesday.

Merck's treatment for urinary, abdominal infections gets FDA approval

The U.S. Food and Drug Administration has approved Merck & Co Inc's combination treatment for complicated forms of urinary tract and abdominal infections, the drugmaker said on Wednesday.

Appeals court mulls reviving Merck's $2.54 billion patent win against Gilead

A federal appeals court on Tuesday was considering whether to reinstate a $2.54 billion jury verdict Merck & Co Inc won against Gilead Sciences Inc in a dispute over hepatitis C treatments — the largest ever in a patent infringement case.

U.S. judge strikes down Trump administration rule requiring drug prices in TV ads

A federal judge on Monday dealt a blow to the Trump administration by striking down a new rule that would have forced pharmaceutical companies to include the wholesale prices of their drugs in television advertising.

Merck CEO sees legal challenge if U.S. adopts drug pricing based on other countries

Merck & Co Chief Executive Ken Frazier said on Thursday a rule to base the price the U.S. government pays for some prescription drugs in it Medicare program on lower prices in other countries would face legal challenges if adopted.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up